Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

Parkinson's disease is a chronic neurodegenerative disorder characterized by the motor
symptoms of bradykinesia, tremor, rigidity and postural instability. However, non-motor …

Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous
disorders exerted through molecular mechanisms that are yet to be completely identified …

Levodopa-induced dyskinesias (LIDs) are the most common and disabling adverse motor
effect of therapy in Parkinson's disease (PD) patients. In this study, we investigated …

Objective: Striatal serotonin projections have been implicated in levodopa‐induced
dyskinesia by providing an unregulated source of dopamine release. We set out to …

Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline
in dopamine levels in the striatum, a breadth of non-motor features and treatment-related …

The causes of neurodegenerative disorders are multiple, and for most of them a mechanistic
understanding is still lacking. However, neurodegenerative diseases such as Alzheimer …

HT1A receptors have long been implicated in the pathogenesis and treatment of anxiety and
depressive disorders. Recently, several lines of studies have revealed new insights into the …

L-dopa-induced dyskinesia (LID) is the most frequent motor complication associated with
chronic L-dopa treatment in Parkinson's disease (PD). Recent advances in the …

Positron emission tomography (PET) imaging studies have shown that peak-dose
dyskinesia is associated to abnormally high levels of synaptic dopamine (DA) in the caudate …